171 related articles for article (PubMed ID: 37453834)
1. [MDS & CMML: Diagnostic and classification].
Wagner-Ballon O; Kosmider O
Bull Cancer; 2023 Nov; 110(11):1106-1115. PubMed ID: 37453834
[TBL] [Abstract][Full Text] [Related]
2. Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies.
Padron E; Steensma DP
Curr Opin Hematol; 2015 Mar; 22(2):163-70. PubMed ID: 25575034
[TBL] [Abstract][Full Text] [Related]
3. [Significance and application value of multiparameter flow cytometry for differentiation of immunophenotype in chronic myelomonocytic leukemia, myelodysplastic syndrome and acute monocytic leukemia].
Wang YX; Zhang JH; Hu YP; Cao FF; Zhang N; Chen F; Liu X; Zhang MY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):857-62. PubMed ID: 22931642
[TBL] [Abstract][Full Text] [Related]
4. PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia.
Chamseddine AN; Cabrero M; Wei Y; Ganan-Gomez I; Colla S; Takahashi K; Yang H; Bohannan ZS; Garcia-Manero G
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S67-73. PubMed ID: 27521329
[TBL] [Abstract][Full Text] [Related]
5. The division of chronic myelomonocytic leukemia (CMML)-1 into CMML-0 and CMML-1 according to 2016 World Health Organization (WHO) classification has no impact in outcome in a large series of patients from the Spanish group of MDS.
Xicoy B; Triguero A; Such E; García O; Jiménez MJ; Arnán M; Bernal T; Diaz-Beya M; Valcárcel D; Pedro C; Ramos F; Amigo ML; Collado R; Palomo L; Ardanaz MT; Cedena MT; Grau J; Zamora L; Sanz G
Leuk Res; 2018 Jul; 70():34-36. PubMed ID: 29775844
[No Abstract] [Full Text] [Related]
6. [Chronic myelomonocytic leukemia (CMML): recent advances in molecular pathogenesis and treatment].
Harada Y; Harada H
Rinsho Ketsueki; 2016 Feb; 57(2):147-55. PubMed ID: 26935632
[TBL] [Abstract][Full Text] [Related]
7. Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022.
Baumgartner F; Baer C; Bamopoulos S; Ayoub E; Truger M; Meggendorfer M; Lenk M; Hoermann G; Hutter S; Müller H; Walter W; Müller ML; Nadarajah N; Blombery P; Keller U; Kern W; Haferlach C; Haferlach T
Blood; 2024 Mar; 143(12):1139-1156. PubMed ID: 38064663
[TBL] [Abstract][Full Text] [Related]
8. Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes.
Wall M
Methods Mol Biol; 2017; 1541():209-222. PubMed ID: 27910026
[TBL] [Abstract][Full Text] [Related]
9. Oligo-monocytic CMML and other pre-CMML states: Clinical impact, prognostication and management.
Valent P
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101137. PubMed ID: 32460976
[TBL] [Abstract][Full Text] [Related]
10. Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.
Reinig E; Yang F; Traer E; Arora R; Brown S; Rattray R; Braziel R; Fan G; Press R; Dunlap J
Am J Clin Pathol; 2016 Apr; 145(4):497-506. PubMed ID: 27124934
[TBL] [Abstract][Full Text] [Related]
11. Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML.
Schuler E; Frank F; Hildebrandt B; Betz B; Strupp C; Rudelius M; Aul C; Schroeder T; Gattermann N; Haas R; Germing U
Leuk Res; 2018 Feb; 65():1-4. PubMed ID: 29216536
[TBL] [Abstract][Full Text] [Related]
12. Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Jachiet V; Moulis G; Hadjadj J; Seguier J; Laribi K; Schleinitz N; Vey N; Sacre K; Godeau B; Beyne-Rauzy O; Bouvet R; Broner J; Brun N; Comont T; Gaudin C; Lambotte O; Le Clech L; Peterlin P; Roy-Peaud F; Salvado C; Versini M; Isnard F; Kahn JE; Gobert D; Adès L; Fenaux P; Fain O; Mekinian A
Haematologica; 2021 May; 106(5):1414-1422. PubMed ID: 33626866
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia.
Cull AH; Mahendru D; Snetsinger B; Good D; Tyryshkin K; Chesney A; Ghorab Z; Reis M; Buckstein R; Wells RA; Rauh MJ
Leuk Res; 2018 Feb; 65():5-13. PubMed ID: 29227812
[TBL] [Abstract][Full Text] [Related]
14. Cytopenia, dysplasia, and monocytosis: a precursor to chronic myelomonocytic leukemia or a distinct subgroup? Case reports and review of literature.
Singh ZN; Post GR; Kiwan E; Maddox AM
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):293-7. PubMed ID: 21658659
[TBL] [Abstract][Full Text] [Related]
15. The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands.
Dinmohamed AG; van Norden Y; Visser O; Posthuma EF; Huijgens PC; Sonneveld P; van de Loosdrecht AA; Jongen-Lavrencic M
Leuk Res; 2015 Feb; 39(2):177-82. PubMed ID: 25533930
[TBL] [Abstract][Full Text] [Related]
16. Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management.
Patnaik MM; Tefferi A
Am J Hematol; 2023 Apr; 98(4):681-689. PubMed ID: 36601682
[TBL] [Abstract][Full Text] [Related]
17. Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by the ELN iMDS flow working group.
Kern W; Westers TM; Bellos F; Bene MC; Bettelheim P; Brodersen LE; Burbury K; Chu SC; Cullen M; Porta MD; Dunlop AS; Johansson U; Matarraz S; Oelschlaegel U; Ogata K; Porwit A; Preijers F; Psarra K; Saft L; Subirá D; Weiß E; van der Velden VHJ; van de Loosdrecht A
Cytometry B Clin Cytom; 2023 Jan; 104(1):51-65. PubMed ID: 36416672
[TBL] [Abstract][Full Text] [Related]
18. Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia.
Palomo L; Ibáñez M; Abáigar M; Vázquez I; Álvarez S; Cabezón M; Tazón-Vega B; Rapado I; Fuster-Tormo F; Cervera J; Benito R; Larrayoz MJ; Cigudosa JC; Zamora L; Valcárcel D; Cedena MT; Acha P; Hernández-Sánchez JM; Fernández-Mercado M; Sanz G; Hernández-Rivas JM; Calasanz MJ; Solé F; Such E;
Br J Haematol; 2020 Mar; 188(5):605-622. PubMed ID: 31621063
[TBL] [Abstract][Full Text] [Related]
19. Chronic myelomonocytic leukaemia (CMML)--a myelodysplastic or myeloproliferative syndrome?
Michaux JL; Martiat P
Leuk Lymphoma; 1993 Jan; 9(1-2):35-41. PubMed ID: 8477199
[TBL] [Abstract][Full Text] [Related]
20. Immunophenotype in chronic myelomonocytic leukemia: is it closer to myelodysplastic syndromes or to myeloproliferative disorders?
Subirá D; Font P; Villalón L; Serrano C; Askari E; Góngora E; Castañón S; Gonzalo R; Mata R; Román A; Llamas P
Transl Res; 2008 May; 151(5):240-5. PubMed ID: 18433705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
